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Effectiveness Analysis Registry between 2000 and 2007. Data were extracted on
publication year, target population, intervention, patient sample, disease, preven-
tion stage, and incremental cost-utility ratio of each economic evaluation. Preven-
tive interventions were defined as measures preventing disease onset. Curative
interventions related to measures identifying patients with risk factors or preclin-
ical disease or interventions limiting disability after harm has occurred. Results
were expressed in terms of costs (valued in 2008 Euro) per quality-adjusted life
year. The association between incremental cost-utility ratios and prevention stage
was examined by means of the Mann-Whitney U-test. RESULTS: The analysis
included 231 studies that reported information about 608 incremental cost-effec-
tiveness ratios. Preventive interventions included interventions that were more
effective and less expensive than comparators (41% of incremental cost-effective-
ness ratios), and interventions that improved outcomes and increased costs (59%).
Both preventive and curative interventions covered the full range of cost-effective-
ness results. However, preventive interventions had a significantly lower median
ratio of 6,255 €per quality-adjusted life year and were thus more cost-effective than
curative interventions (12,917 € per quality-adjusted life year) (p  0.002).
CONCLUSIONS:Although the cost-effectiveness of preventive interventions varies
substantially, preventive interventions tended to be more cost-effective than cu-
rative interventions.
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TENDERING OF BIOSIMILARS IN THE UK – DOES LAUNCH PRICE ACTUALLY
MATTER?
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OBJECTIVES: In the light of the austerity drives and cost containment practices,
payers increasingly resort to procurement procedures in order to award contracts
for the supply of both conventional drugs and biosimilars. The tough reality of
health care economics in conjunction with the commitment of large generic man-
ufacturers, who continue to invest despite the challenges, may mean that tender-
ing of biosimilars may actually be a tool to increase biosimilars’ market share by
demonstrating price competitiveness.This study aims to evaluate how initial list
price, together with other considerations about efficacy and safety, could influence
the hospital formulary inclusion of new biosimilar drugs in the UK. METHODS: A
data framework was developed from secondary research of existing biosimilar list
prices, product profiles, clinical data submitted and current landscape. The frame-
work was validated through phone-based interviews across different regions in the
UK (n10) targeting Hospital procurement Pharmacists in 2011. RESULTS:Majority
of respondents indicated price to be the primary criteria for formulary inclusion
although some pharmacists highlighted efficacy and safety parameters as influ-
encing factorsCONCLUSIONS:The development of clinical commissioning consor-
tia and the expansion of the biosimilar market as major biologicals come off patent
mean that more decisions about biosimilar purchasing could be made jointly with
primary care. Tendering as a mode of procurement for biosimilars, removes the
prescriber’s influence which is the acceptance-limiting step for biosimilars cur-
rently due to the concerns on efficacy and safety. From a hospital procurement
pharmacists’ point of view, it is unclear whether a price discount strategy will
favour the introduction of new biosimilars in the UK hospitals as other factors
might have a more important role in the final purchasing decision.
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OBJECTIVES: Physiotherapy services are reimbursed on a fee for service method in
the ambulatory care in Hungary. The aim of this study is to analyze the utilization
of physiotherapy services in Hungary. METHODS: Data were derived from the fi-
nancial database of the National Health Insurance Fund Administration, the only
health care financing agency in Hungary. We analyzed the year 2008. Medical pro-
cedures which can be performed by physiotherapists were included into the study.
Medical procedures are listed according to the Hungarian version of the Interna-
tional Classification of Procedures in Medicine of WHO. RESULTS: Altogether 151
medical procedures were used by physiotherapists. The following top-11 medical
procedure were responsible for more than half (52.5 %) of total activities: ultra-
sound therapy (8.2 %), iontophorezis (6.5 %), muscle strengthening exercise (4.8 %),
individual training (4.4 %), training for circulation improvement (4.1 %), hand mas-
sage (4.0 %), passive movement of multiple limb (4.0 %), middle frequency treat-
ment (3.8 %), mobilization of joints (3.3 %), exercises against resistance (3.2 %),
education of using medical devices (3.1 %), extension of contracture (3.1 %). Total
annual health insurance reimbursement of physiotherapy services was 7.34 billion
Hungarian Forint (42.7 million USD; 29.2 million EUR). CONCLUSIONS: Physiother-
apy care proved to be a highly concentrated health service where 11 medical pro-
cedures out of 151 are responsible of more than half of activity and health insur-
ance reimbursement.
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OBJECTIVES: ISPOR’s mission is to increase the efficiency, effectiveness, and fair-
ness with which the available health care resources are used to improve health
together with a strong vision be recognized globally as the authority for outcomes
research and its use in health care decisions towards improved health. Despite
modest increases, the membership and conference attendance of health care de-
cision makers still remains low, relative to those involved in academia, industry
and consultancy. Assessing if some of those responsible for utilising HEOR data in
care provision and care practice are aware of ISPOR and its full resources and the
drivers and barriers for involvement could provide an opportunity for increased
membership and active involvement. METHODS: To elucidate the level of aware-
ness of ISPOR, its publications and other resources, interviews were undertaken
with stakeholders within 12 NHS Cancer Networks in the UK. A data framework
was developed to support a series of structured telephone interviews according to
the British Healthcare Business Intelligence (BHBIA) Legal and Ethical Guidelines
for Healthcare Market Research. RESULTS: Spontaneous awareness of ISPOR is
relatively limited within the NHS Cancer Network stakeholders, with even less
awareness to Value in Health. Notable areas of interest were Oncology, Patient Ad-
herence and Persistence and Patient Reported Outcomes Measures. The main bar-
riers to membership of ISPOR was its initial awareness and more effective involve-
ment would be limited due to existing NHS commitments, financial resources and
levels of individual interest /relevance to existing NHS role. Organisational involve-
ment with NHS stakeholder networks would support increased levels of
engagement. CONCLUSIONS: To enhance the awareness of ISPOR, its resources,
conferences and educational support, ISPOR should consider a more targeted
awareness campaign with key NHS clinical networks such as NHS Cancer Net-
works, British Oncology Pharmacy Association and evolving Clinical Commission-
ing Groups.
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OBJECTIVES: Therapeutic monoclonal antibodies (mAbs) are capturing an increas-
ingly larger proportion of the pharmaceutical market. Their specificity for biologi-
cal targets allows them to effectively treat a variety of indications. Yet, despite their
successes, the various stakeholders’ viewpoints in European Union (EU) countries
are often at odds. We explore mAbs as a drug class, specifically, how they are
approved for use by the European Medicines Agency (EMA) and other regulating
bodies and how stakeholders’ opinions diverge from regulatory decisions.
METHODS:The following were summarized for mAbs approved for use in EU coun-
tries from 2000-2011: regulatory approval decisions; comparing and contrasting
payer coverage decisions in selected EU countries; and position statements from
patients, advocacy groups, and medical organizations. Discrepancies between ini-
tial or post-approval regulatory decisions and the statements of the other stake-
holders were highlighted. RESULTS: Nineteen mAbs have been approved by the
EMA during the past 10 years. The summary data show how stakeholders use
clinical data to reinforce their agenda. For instance, bevacizumab has been under-
going battles in both the US and the EU: regulators want to remove specific labeled
indications based on safety and effectiveness data and NICE has advised against
coverage for treating metastatic colorectal cancer, citing inadequate benefits for
the costs, while patients fight for continued access to the therapy to extend their
life at all costs. CONCLUSIONS: After product approval, physicians have tradition-
ally been the key treatment decision makers; however, the influence of other stake-
holders are increasingly affecting the availability and use of drugs. The discordance
between decisions made by regulators and payers has forced drug manufacturers
to not only show that it is safe and efficacious to regulators, but to demonstrate a
product’s value to patients and payers. Incorporating the viewpoints of payers as
well as patients in the drug development process will narrow the gap between
stakeholders.
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OBJECTIVES: Recent increase in competition among hospitals, and managed care,
and the impact of Medicare Prospective Payment System; properly measured hos-
pital performance has become important to evaluate the impact of policies on the
hospital industry. This study assessed the influence of hospital governance on
hospital’s economic performance and efficiency, and it also attempted to system-
atically address the issue of ‘whether participation by insider and outsider busi-
ness community stakeholders on the hospital governing board is related to hospi-
tal’s economic performance’. METHODS: The study was focused on 144
community hospitals in Tennessee; those provided general and acute care services
from 2000 to 2006. An input-oriented and output-oriented Data Envelopment Anal-
ysis (DEA) using multiple input and output variables, which is non-parametric,
flexible, and a mathematical programming approach for the performance assess-
ment, was used to measure the efficiency by estimating the optimum level of
output, conditional upon the mix of inputs. RESULTS: It was found that urban
community hospitals were relatively more efficient than rural community hospi-
tals, and smaller community hospitals were relatively more efficient than their
larger and medium-sized counterparts. Interestingly, the results revealed that
small-sized urban hospitals were relatively more efficient than any other commu-
nity hospital type. From a management and policy perspective type, the study
indicates that both rural and large community hospitals may use urban or small
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